CARLSBAD

ValueCoach AI Tool Announced by ValueSelling Associates at Gartner CSO & Sales Leader Conference 2024

Retrieved on: 
화요일, 5월 21, 2024
CRMS, ICPS, Learning, Organization, Conference, Associate, Gartner, AI, Microsoft Dynamics, GPT, Salesforce, LMS, Sales

LAS VEGAS, May 21, 2024 (GLOBE NEWSWIRE) -- Gartner CSO & Sales Leader Conference - ValueCoach AI™, the first value-based artificial intelligence (AI) coaching tool engineered to empower revenue teams to drive desired selling behaviors and enable sales managers to optimize sales coaching and performance efficiently, will be announced today by ValueSelling Associates, Inc. ValueSelling Associates is a proud sponsor of the Gartner CSO & Sales Leader Conference taking place May 21-22 in Las Vegas.

Key Points: 
  • LAS VEGAS, May 21, 2024 (GLOBE NEWSWIRE) -- Gartner CSO & Sales Leader Conference - ValueCoach AI™, the first value-based artificial intelligence (AI) coaching tool engineered to empower revenue teams to drive desired selling behaviors and enable sales managers to optimize sales coaching and performance efficiently, will be announced today by ValueSelling Associates, Inc. ValueSelling Associates is a proud sponsor of the Gartner CSO & Sales Leader Conference taking place May 21-22 in Las Vegas.
  • Built on the proven ValueSelling Framework® sales methodology with over 260 proprietary training modules, ValueCoach AI is set to revolutionize sales performance.
  • ValueCoach AI comes with a suite of capabilities to help sales teams substantially boost sales coaching efficiency and sales productivity.
  • Booth #118 - ValueSelling Associates will exhibit at booth #118 at the Gartner CSO & Sales Leader Conference, showcasing how ValueCoach AI can help transform sales operations.

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Retrieved on: 
화요일, 5월 21, 2024
Asian literature, IBD, DDW, Disease, Patient, Inflammation, UC, PDE4, Toxicity, DAI, BID, Trial of the century, DSS, AUC, Apremilast, Mouse, Vomiting, Psoriasis, CMO, Internal bleeding, Autoimmunity, Poster, Human body weight, Therapy, Dog, Model, Drinking water, Pharmaceutical industry

The poster is available on the Scientific Publications page of the Company’s website .

Key Points: 
  • The poster is available on the Scientific Publications page of the Company’s website .
  • PALI-2108 demonstrates similar target engagement to the PDE4 inhibitor, apremilast, which is approved for use in psoriasis and psoriatic arthritis.
  • Importantly, PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in UC patients.
  • No systemic toxicity in dogs and large therapeutic window due to local activation.

AppTech Payments Announces Commercial Launch of its Banking-as-a-Service (BaaS) Platform Following Successful Pilot Program

Retrieved on: 
목요일, 5월 16, 2024
FedNow, Intel, Friction, Wells Fargo, ACH, Bank of America, Venmo, Chase, Fortune 1000, Bank, As a service, Organization, Commerce, Knowledge, SMS

CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (Nasdaq: APCX), a pioneering Fintech company powering frictionless commerce, announces today the successful completion of the pilot program for its Banking-as-a-Service (BaaS) platform.

Key Points: 
  • CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (Nasdaq: APCX), a pioneering Fintech company powering frictionless commerce, announces today the successful completion of the pilot program for its Banking-as-a-Service (BaaS) platform.
  • The Company will use this BaaS solution to commercially launch InstaCash , which utilizes the BaaS for virtual accounts, debit and credit cards, and high interest-yielding financial products.
  • AppTech CEO Luke D’Angelo stated, “The success of our BaaS pilot program signifies a significant milestone as we continue our mission to democratize banking by providing small and medium-sized enterprises access to products traditionally reserved for Fortune 1000 companies.
  • By integrating online financial literacy courses directly into the InstaCash platform, AppTech aims to equip its users with the knowledge and skills needed to navigate the complexities of personal finance effectively.

Selling Power Magazine Chooses ValueSelling Associates as a Top Sales Training Company for 2024

Retrieved on: 
목요일, 5월 16, 2024
ChromeOS, AI, Associate, VPS, Organization, Sales

CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- V alueSelling Associates, Inc. is honored to be selected to Selling Power’s Top Sales Training Companies 2024 list as a best-in-class sales training provider.

Key Points: 
  • CARLSBAD, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- V alueSelling Associates, Inc. is honored to be selected to Selling Power’s Top Sales Training Companies 2024 list as a best-in-class sales training provider.
  • Selling Power magazine editors say Chief Revenue Officers (CROs), sales VPs, and sales enablement leaders can leverage this list to find the right sales training partner to help salespeople succeed.
  • ValueSelling Associates offers customized sales training, sales coaching, and consulting services – both in-person and virtually – to keep it simple and drive sales results.
  • Consistently ranked as a Top Sales Training company by both Selling Power and Training Industry, ValueSelling Associates has also earned a 4.9 out of 5-star rating on Gartner Peer Insights ™ (as of May 16, 2024), a site that offers in-depth client reviews.

AppTech Payments Corp. Reports Strong Start to 2024 with Positive First Quarter Financial Results and Strategic Business Advances

Retrieved on: 
수요일, 5월 15, 2024
Partnership, Fintech, Planet, SAN, Conference, Growth, Pharmaceutical industry

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (NASDAQ: APCX), a pioneering Fintech company powering frictionless commerce, today announced its financial results for the first quarter ended March 31, 2024, demonstrating significant revenue growth and strategic progress.

Key Points: 
  • SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (NASDAQ: APCX), a pioneering Fintech company powering frictionless commerce, today announced its financial results for the first quarter ended March 31, 2024, demonstrating significant revenue growth and strategic progress.
  • Conference Presentation: Presented at the Planet MicroCap Conference in April 2024, where we received positive feedback on AppTech’s innovative solutions.
  • “Our first quarter performance reflects the successful execution of our strategic initiatives and our continuous commitment to innovation and customer satisfaction,” stated Luke D’Angelo, AppTech Payments Corp. Chairman and CEO.
  • “With our advanced digital platform and strong market positioning, we are well-equipped to sustain our growth trajectory and enhance value for our shareholders.”

Natural Alternatives International, Inc. Announces Fiscal 2024 Q3 and YTD Results

Retrieved on: 
화요일, 5월 14, 2024
Security (finance), Natural Alternatives International, Partnership, NAI, Growth, Annual report

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 13% to $2.7 million during the third quarter of fiscal year 2024, as compared to $2.3 million for the third quarter of fiscal year 2023.

Key Points: 
  • CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 13% to $2.7 million during the third quarter of fiscal year 2024, as compared to $2.3 million for the third quarter of fiscal year 2023.
  • The increase in CarnoSyn® beta-alanine royalty, licensing, and raw material sales revenue during the third quarter of fiscal 2024 was primarily due to increased royalty income and favorable volume rebate activity.
  • On April 2, 2024, we announced we will be reopening this facility in May 2024.
  • Based on our current overall sales forecast, we anticipate we will experience a net loss in the fourth quarter of fiscal 2024 and an overall net loss for fiscal 2024.

JLab Unveils JBuddies Studio 2 Headphones: Redefining Kid-Friendly Audio Technology

Retrieved on: 
화요일, 5월 14, 2024
Cloud, Foam, Parent, System, Bluetooth, Safety, Life, Walmart, Target, Comfort, Headphones, GroovyLab, Frustration, Cassette tape

San Diego, CA, May 14, 2024 (GLOBE NEWSWIRE) -- JLab , a leader in personal technology, unveils the JBuddies Studio 2 Headphones, an innovative product designed specifically for kids that redefines audio experiences at an affordable price.

Key Points: 
  • San Diego, CA, May 14, 2024 (GLOBE NEWSWIRE) -- JLab , a leader in personal technology, unveils the JBuddies Studio 2 Headphones, an innovative product designed specifically for kids that redefines audio experiences at an affordable price.
  • With the JBuddies Studio 2 Headphones, we continue this legacy,” said Win Cramer, CEO of JLab.
  • Additionally, JBuddies Studio 2 Wireless Headphones introduces a new innovative Wireless Share Mode, allowing two children to enjoy synchronized audio experiences from a single device.
  • Designed with young users in mind, JBuddies Studio 2 Headphones boasts intuitive earcup controls, empowering children to navigate their own audio experience effortlessly.

CB Therapeutics Introduces Sustainable Retinol Production

Retrieved on: 
목요일, 5월 9, 2024
Vitamin A, Retinol, Therapy, Biotechnology, Carbon footprint, Skin, CSO, CB, Fine chemical

Carlsbad, California--(Newsfile Corp. - May 9, 2024) - CB Therapeutics , a premier biotechnology firm specializing in precision fermentation, proudly unveils its latest breakthrough: Retinol, the quintessential solution for achieving radiant and youthful skin.

Key Points: 
  • Carlsbad, California--(Newsfile Corp. - May 9, 2024) - CB Therapeutics , a premier biotechnology firm specializing in precision fermentation, proudly unveils its latest breakthrough: Retinol, the quintessential solution for achieving radiant and youthful skin.
  • Long revered by skincare experts for its transformative properties, Retinol, a derivative of vitamin A, now enters a new era of production thanks to CB Therapeutics' cutting-edge precision fermentation and synthetic biology techniques.
  • This groundbreaking process revolutionizes Retinol production, enabling rapid, clean, and eco-friendly synthesis of both the compound itself and its derivatives.
  • Sher Butt, CEO of CB Therapeutics, expressed enthusiasm about this development, highlighting the global demand for eco-friendly alternatives in the skincare industry.

Acutus Medical Reports First Quarter 2024 Financial Results

Retrieved on: 
목요일, 5월 9, 2024
Sale, OTC, Electrophysiology, GAAP, AFIB, Cryptocurrency

CARLSBAD, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the first quarter of 2024.

Key Points: 
  • CARLSBAD, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the first quarter of 2024.
  • Revenue from Continuing Operations was $3.6 million for the first quarter of 2024, an increase of 192% compared to $1.2 million for the first quarter of 2023.
  • Gross margin on a GAAP basis for continuing operations was negative 1% for the first quarter of 2024 compared to negative 70% for the same quarter last year.
  • Loss on discontinued operations was $0.4 million for first quarter of 2024, compared to $12.0 million for the same period last year.

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Retrieved on: 
수요일, 5월 8, 2024
Patient, Design, Research, DMPK, IND, Observational study, HD, GLP, FA, DM1, HTT, Therapy, Biotechnology, G&A, Pharmaceutical industry

CARLSBAD, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced first quarter 2024 financial results along with recent business highlights and upcoming milestones.

Key Points: 
  • Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients
    CARLSBAD, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced first quarter 2024 financial results along with recent business highlights and upcoming milestones.
  • Design is on track to complete GLP studies for DT-216P2 by year-end 2024 to start patient trials in 2025.
  • R&D Expenses: Research and development (R&D) expenses were $9.8 million for the quarter ended March 31, 2024.
  • G&A Expenses: General and administrative (G&A) expenses were $4.6 million for the quarter ended March 31, 2024.